von Willebrand factor D and EGF domainsGenealiases: []
Q-omics provides the consensus-scored VWDE profile across patient tissues and cancer cell-line models. VWDE expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, VWDE is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, VWDE RNA expression shows 15,260 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, LUAD, and TGCT as cancer lineages where VWDE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VWDE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VWDE survival associations across molecular data types. VWDE RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VWDE RNA expression–survival associations across cancer types. High VWDE expression shows unfavorable associations in UCEC, KIRP, LGG, COAD and STAD, but favorable associations in ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for VWDE RNA expression.
This table summarizes VWDE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for VWDE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VWDE shows lower tumor expression in BRCA, KIRC and LIHC and higher tumor expression in LUAD, KIRP and LUSC. The LUAD box plot shows higher VWDE RNA expression in tumor versus normal tissue (log2 FC = +1.308, t-test p < 0.001).
This table shows molecular features associated with VWDE in patient tissues and cancer cell lines. In patient samples, VWDE shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, VWDE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
